Citadel Advisors
NYMX

Citadel Advisors’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Citadel Advisors’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,100
Closed -$969 – 15627
2023
Q2 		$969 Sell
5,100
-7,300
-59% -$2.87K ﹤0.01% 14011
2023
Q1 		$4.22K Sell
12,400
-3,400
-22% -$1.38K ﹤0.01% 13975
2022
Q4 		$4.69K Buy
+15,800
New +$5.72K ﹤0.01% 14075
2022
Q2 		– Sell
-12,700
Closed -$16K – 14580
2022
Q1 		$16K Buy
+12,700
New +$19.6K ﹤0.01% 13306
2021
Q4 		– Sell
-27,900
Closed -$57K – 15145
2021
Q3 		$57K Buy
27,900
+15,100
+118% +$26.8K ﹤0.01% 13297
2021
Q2 		$20K Sell
12,800
-2,800
-18% -$5.19K ﹤0.01% 13538
2021
Q1 		$35K Buy
+15,600
New +$41.1K ﹤0.01% 13006
2020
Q3 		– Sell
-28,000
Closed -$99K – 10960
2020
Q2 		$99K Buy
28,000
+8,900
+47% +$28.1K ﹤0.01% 9003
2020
Q1 		$45K Buy
+19,100
New +$53.6K ﹤0.01% 9079
2019
Q4 		– Sell
-11,000
Closed -$20K – 9962
2019
Q3 		$20K Sell
11,000
-8,600
-44% -$15K ﹤0.01% 8942
2019
Q2 		$28K Buy
19,600
+6,300
+47% +$11K ﹤0.01% 8888
2019
Q1 		$26K Sell
13,300
-6,900
-34% -$14.6K ﹤0.01% 9017
2018
Q4 		$26K Buy
+20,200
New +$37K ﹤0.01% 8667
2018
Q2 		– Sell
-17,700
Closed -$75K – 9431
2018
Q1 		$75K Sell
17,700
-2,900
-14% -$10.1K ﹤0.01% 7815
2017
Q4 		$68K Sell
20,600
-1,000
-5% -$3.65K ﹤0.01% 7549
2017
Q3 		$83K Sell
21,600
-24,100
-53% -$91.4K ﹤0.01% 7087
2017
Q2 		$201K Buy
45,700
+13,900
+44% +$57.1K ﹤0.01% 6565
2017
Q1 		$115K Buy
31,800
+1,900
+6% +$6.25K ﹤0.01% 6806
2016
Q4 		$80K Sell
29,900
-17,900
-37% -$55.5K ﹤0.01% 6753
2016
Q3 		$156K Buy
47,800
+20,400
+74% +$66.7K ﹤0.01% 6445
2016
Q2 		$92K Buy
+27,400
New +$67.3K ﹤0.01% 6229
2015
Q3 		– Sell
-2,700
Closed -$4K – 9335
2015
Q2 		$4K Buy
2,700
+1,900
+238% +$2.65K ﹤0.01% 8575
2015
Q1 		$1K Buy
+800
New +$378 ﹤0.01% 8464
2014
Q4 		– Sell
-7,800
Closed -$34K – 8807
2014
Q3 		$34K Sell
7,800
-19,700
-72% -$96.6K ﹤0.01% 7142
2014
Q2 		$136K Buy
+27,500
New +$142K ﹤0.01% 5952

Other funds holding NYMX

DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return
CAM
Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return
ODIJL
One Day In July LLC Burlington, Vermont $1.44B AUM 17.18% 1-Year Est. Return

Citadel Advisors's NYMX Position: Q3 2023 in Review

Citadel Advisors sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 25,040 shares — an estimated $4.76K sold.

Citadel Advisors first reported a position in NYMX in Q1 2014 and held it in 20 quarters. The position peaked at $216K in Q1 2014. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

  • Citadel Advisors reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 25,040 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $4.76K.
  • Citadel Advisors first reported a position in Nymox Pharmaceutical Corp in Q1 2014 and held it in 20 quarters.
  • Citadel Advisors's Nymox Pharmaceutical Corp position peaked at $216K in Q1 2014.
  • 5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.